381 related articles for article (PubMed ID: 28570035)
1. Metabolic rewiring in mutant Kras lung cancer.
Kerr EM; Martins CP
FEBS J; 2018 Jan; 285(1):28-41. PubMed ID: 28570035
[TBL] [Abstract][Full Text] [Related]
2. Targeting
Uras IZ; Moll HP; Casanova E
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560574
[TBL] [Abstract][Full Text] [Related]
3. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
4. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Zhang J; Park D; Shin DM; Deng X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
[TBL] [Abstract][Full Text] [Related]
6. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
7. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
9. Targeting metabolic reprogramming in KRAS-driven cancers.
Kawada K; Toda K; Sakai Y
Int J Clin Oncol; 2017 Aug; 22(4):651-659. PubMed ID: 28647837
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations in lung cancer.
Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
[TBL] [Abstract][Full Text] [Related]
11. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
12. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
13. KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC).
Chen H; Zhao J
Thorac Cancer; 2020 Dec; 11(12):3425-3435. PubMed ID: 33022831
[TBL] [Abstract][Full Text] [Related]
14. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
15. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
16. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
[TBL] [Abstract][Full Text] [Related]
17. KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives.
Guibert N; Ilie M; Long E; Hofman V; Bouhlel L; Brest P; Mograbi B; Marquette CH; Didier A; Mazieres J; Hofman P
Curr Mol Med; 2015; 15(5):418-32. PubMed ID: 25941815
[TBL] [Abstract][Full Text] [Related]
18. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
19. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
20. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
